Datapoint: FDA Approves TG Therapeutics’ Ukoniq
The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data suggests it may be safer than its rival PI3K inhibitors, including Gilead Sciences’ Zydelig and Bayer’s Aliqopa, and the FDA will not require a black box warning on the new drug. For the treatment of marginal zone lymphoma, Zydelig currently holds preferred formulary placement for 17% of covered lives, compared to Aliqopa’s 4%.
SOURCE: MMIT Analytics, as of 2/10/21